Intrabio Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Therapeutic Agents for Treating Restless Leg Syndrome (US 11,660,279) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject (US 11,690,830) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Therapeutic Agents for Neurodegenerative Diseases (US 11,793,782) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,905,670 | Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive Function In force · High confidence | In force | High confidence | |
| US 11,400,067 | Pharmaceutical Compositions and Uses Directed to Lysosomal Storage Disorders In force · High confidence | In force | High confidence | |
| US 11,998,518 | Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive Function In force · High confidence | In force | High confidence | |
| US 12,144,792 | Therapeutic Agents for Neurodegenerative Diseases In force · High confidence | In force | High confidence | |
| US 12,329,733 | Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive Function In force · High confidence | In force | High confidence | |
| US 12,433,862 | Pharmaceutical Compositions and Uses Directed to Lysosomal Storage Disorders In force · High confidence | In force | High confidence | |
| US 12,433,863 | Pharmaceutical Compositions and Uses Directed to Lysosomal Storage Disorders In force · High confidence | In force | High confidence | |
| US 12,121,513 | Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject In force · High confidence | In force | High confidence | |
| US 11,690,830 | Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject In force · High confidence | In force | High confidence | |
| US 11,083,718 | Betahistine, or a Pharmaceutically Acceptable Salt Thereof, and a Monoamine Oxidase Inhibitor, for Use in the Treatment or Prevention of One or More Symptoms of Vertigo in a Subject In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending